Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This project aims to a) evaluate the effects of haloperidol, olanzapine, and risperidone in
combination with valproate on insulin secretion and insulin actions, b) evaluate medication
effects on abdominal fat, total body fat and total fat-free mass, and c) evaluate treatment
effects on glucose tolerance, lipid profiles, and plasma levels of leptin, adiponectin,
ghrelin and C-reactive protein. Hypotheses will be evaluated by measuring 1) insulin action
and secretion using frequently sampled intravenous glucose tolerance tests, 2) body
composition using dual energy x-ray absorptiometry, magnetic resonance scans, and
anthropomorphic measurements, and 3) changes in hormone levels and lipid profiles. The aims
will be addressed in non-diabetic schizophrenia patients chronically treated with
haloperidol, olanzapine or risperidone who will have valproate added to their treatment.
Relevant data is critically needed to target basic research, identify long-term
cardiovascular risks, and plan therapeutic interventions.